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BACKGROUND AND PURPOSE: Data about variations in stroke incidence and subsequent major adverse outcomes are essential 
to inform secondary prevention and prioritizing resources to those at the greatest risk of major adverse end points. We aimed 
to describe the age, sex, and socioeconomic differences in the rates of first nonfatal stroke and subsequent major adverse 
outcomes.
METHODS:  The cohort study used linked Clinical Practice Research Datalink and Hospital Episode Statistics data from the 
United Kingdom. The incidence rate (IR) ratio of first nonfatal stroke and subsequent major adverse outcomes (composite 
major adverse cardiovascular events, recurrent stroke, cardiovascular disease-related, and all-cause mortality) were calculated 
and presented by year, sex, age group, and socioeconomic status based on an individual’s location of residence, in adults with 
incident nonfatal stroke diagnosis between 1998 and 2017.
RESULTS: A total of 82 774 first nonfatal stroke events were recorded in either primary care or hospital data—an IR of 109.20 
per 100 000 person-years (95% CI, 108.46–109.95). Incidence was significantly higher in women compared with men (IR 
ratio, 1.13 [95% CI, 1.12–1.15]; P<0.001). Rates adjusted for age and sex were higher in the lowest compared with the 
highest socioeconomic status group (IR ratio, 1.10 [95% CI, 1.08–1.13]; P<0.001). For subsequent major adverse outcomes, 
the overall incidence for major adverse cardiovascular event was 38.05 per 100 person-years (95% CI, 37.71–38.39) with a 
slightly higher incidence in women compared with men (38.42 versus 37.62; IR ratio, 1.02 [95% CI, 1.00–1.04]; P=0.0229). 
Age and socioeconomic status largely accounted for the observed higher incidence of adverse outcomes in women.
CONCLUSIONS: In the United Kingdom, incidence of initial stroke and subsequent major adverse outcomes are higher in 
women, older populations, and people living in socially deprived areas.
GRAPHIC ABSTRACT: An online graphic abstract is available for this article.
Key Words: cardiovascular diseases ◼ epidemiology ◼ incidence ◼ population ◼ secondary prevention
Stroke is the second leading cause of death glob-ally1 and a leading cause of disability worldwide.2 The aging population and treatment improve-
ments are expected to significantly impact on stroke 
epidemiology3—the number of stroke survivors is on the 
rise, impacting the need for poststroke facilities and the 
risk of stroke recurrence.4 About 1 in 4 stroke survivors 
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advances in the management of patients with stroke, 
mortality, and disability rates remain high.6
There is a lack of contemporary evidence from nation-
ally representative data across the entire spectrum of 
both primary and secondary care to assess demographic 
variations in the incidence of first nonfatal stroke. Most 
published estimates of stroke incidence in the United 
Kingdom only capture certain types of stroke, may or 
may not include recurrent stroke, focus on small nonrep-
resentative populations or a short time period.7–9 More-
over, the sex and age variations for the incidence of major 
adverse outcomes after the first stroke have either been 
in selected populations with incident ischemic stroke and 
above a predefined age.10,11 To identify patterns and any 
discrepancies in care of patients, information on temporal 
trends in sex- and age-related differences with respect 
to the incidence of stroke and subsequent major adverse 
outcomes is needed. This can inform resource allocation 
and policy to enhance clinical care and outcomes.
We sought to update current knowledge on differ-
ences in nonfatal stroke incidence and incidence of 
major adverse outcomes following the first nonfatal 
stroke event. We used linked electronic health record 
from primary care consultations, secondary care (hos-
pital admissions and procedure-level data), and the 
national death registry that are representative of the 
UK population. This population-based study explores 
demographic variations in incidence of stroke (first-
ever nonfatal stroke) and incidence of major adverse 
outcomes after first-ever stroke among individuals aged 
18 years and over.
METHODS
Data Availability
The data that support the findings of this study are available 
from Clinical Practice Research Datalink (CPRD). Restrictions 
apply to the availability of the data, which was used under 
license for the current study, and so are not publicly available. 
However, data is available upon application to CPRD.
Data Source
This prospective cohort study used the UK CPRD GOLD of 
primary care electronic health records,12 linked to Hospital 
Episode Statistics (HES),13 Office for National Statistics mortal-
ity data,14 and social deprivation data.15 CPRD collects deidenti-
fied patient data (including diagnoses, symptoms, prescriptions, 
referrals, and tests) from data quality-assured GP practices 
across the United Kingdom.12 Patients in CPRD are broadly 
representative of the UK general population in terms of sex, 
age, and ethnicity.12,16 CPRD is very widely used internationally 
for epidemiological research and has been used to produce over 
1000 research studies, published in peer-reviewed journals 
across a broad range of health outcomes.12 HES is a national 
database containing dates and diagnostic codes for all elective 
and emergency admissions and procedures to National Health 
Service hospitals in England (https://www.hscic.gov.uk/hes). 
Office for National Statistics provides data on cause-specific 
mortality and corresponding dates obtained from death certifi-
cates for all residents in the United Kingdom.14 This study was 
approved by the Independent Scientific Advisory Committee of 
the Medicines and Health care products Regulatory Agency 
(Protocol number 19_023R).
Study Population
We identified a cohort of patients with first record of nonfatal 
stroke in either CPRD GOLD or HES data between January 
1, 1998, and December 31, 2018. Patients entered the study 
cohort at minimum date of study start (January 1, 1998); being 
aged 18 years and over; with at least 12 months of registra-
tion17; practice data of acceptable quality (up-to-standard—
Method in the Data Supplement); and eligible for linkage to 
HES. The follow-up end date was defined as the date of trans-
fer out/leaving the practice, date of death, last date for CPRD-
HES link, or the last date of data collection, whichever came 
earliest. Patients with a prior history of stroke before the study 
start date (January 1, 1998) were excluded from the study—
5621 records between 1914 and 1997.
To assess the incidence of subsequent major adverse out-
comes, the cohort consisted of patients with no prior history of 
major adverse event (ie, coronary heart disease [CHD], includ-
ing coronary revascularization, peripheral vascular disease 
[PVD], or heart failure). Patients were followed until they devel-
oped a major adverse outcome or left the original cohort. Figure 
I in the Data Supplement shows the study flow diagram.
Identifying Patients, Patient Characteristics, and 
Outcomes
To identify patients with stroke and outcomes of interest, we 
adapted the code list from the CALIBER code repository18 
(https://www.caliberresearch.org/portal/)—from CPRD GOLD 
using Read codes, from HES using International Classification 
of Diseases, Tenth Revision codes and Office of Population 
Censuses and Surveys Classification of Surgical Operations 
and Procedures revision 4.6 for procedure codes—Table I in 
the Data Supplement. We also extracted information on demo-
graphic factors, including age and sex, socioeconomic status 
(SES), and ethnicity. For SES, a key determinant for health, we 
used the English Index of Multiple Deprivation (IMD) 201515 
which is a widely used composite measure of deprivation. The 
Nonstandard Abbreviations and Acronyms
CHD coronary heart disease
CPRD Clinical Practice Research Datalink
CVD cardiovascular disease
HES Hospital Episode Statistics
IMD index of multiple deprivation
IR incidence rate
IRR incidence rate ratio
MACE major adverse cardiovascular events
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current IMD measure quantifies relative deprivation across 7 
different domains of deprivation: income; employment; educa-
tion, skills, and training; health and disability; crime; barriers to 
housing and services; and living environment, using an area-
based model at a low geography of about 1500 people.19 The 
overall IMD is calculated as a weighted mean across the 7 
domains, hence, offers a single score to describe the concept 
of deprivation whiles recognizing the many interacting com-
ponents. SES is ranked into quintiles (quintile 1: highest SES 
group to quintile 5: lowest SES group).
The outcomes of interest were subsequent major adverse 
events (composite major adverse cardiovascular events [MACE], 
recurrent stroke, cardiovascular disease [CVD]-related, and all-
cause mortality) after incident stroke. MACE was defined as a 
composite of CHD, stroke, PVD, heart failure, and CVD-related 
death) based on records from CPRD GOLD, HES, or Office for 
National Statistics registries.
Statistical Analysis
Baseline characteristics were presented by sex and expressed 
using mean and SD for continuous variables (after assess-
ment of the normality of data) and percentages for categorical 
variables. Differences for categorical and continuous variables 
were assessed using the χ2 and t tests, respectively. Incidence 
rates (IRs) per 100 000 person-years for stroke were calcu-
lated by dividing the number of individuals with a stroke by the 
number of person-years of all patient in the original cohort. IRs 
were presented by age (5-year intervals), sex, and year of diag-
nosis. IR ratios (IRRs) for IMD quintiles were adjusted for age 
and sex in a Poisson regression model.
We calculated the IRs per 100 person-years for subse-
quent major adverse outcomes in the cohort of patients with 
no prior history of major adverse event. A sensitivity analysis 
was restricted to the cohort of patients with subsequent major 
adverse outcomes occurring after 30 days of the index stroke 
was done. Patients with other associated major adverse end 
points are more likely to remain in hospital for an extended 
period following admission for their incident stroke event. The 
recording of such hospital (secondary care) activity in pri-
mary care records through discharge letters or referral notes 
from specialists may be delayed. The date of referral/letter 
may erroneously be recorded as the date of stroke or associ-
ate major adverse outcome. Some outcome events may only 
be recorded when a posthospitalization visit to primary care 
occurs. Hence, a 30-day interval was chosen because records 
for adverse outcomes occurring within 30 days is likely to be 
related to index stroke event.20,21
The study findings are reported in accordance with the 
Reporting of Studies Conducted Using Observational Routinely 
Collected Health Data recommendations.22 All statistical analy-
ses were performed using Stata 16.1 (StataCorp LP), and sta-
tistical significance was set at P<0.05.
RESULTS
A total of 9 992 380 individuals 18 years and over were 
identified in CPRD GOLD with a total follow-up time of 
75 794 468.8 person-years between January 1, 1998, 
and December 31, 2017. The mean follow-up time 
was 1.81 years (SD: 2.78) with a median of 0.51 years 
(interquartile range, 0.05–2.41). There were 82 774 indi-
viduals with incident nonfatal stroke. There were 44 614 
(53.9%) women. The mean age at incident stroke was 
74.3 year (SD: 13.6). Males had incident stroke at a 
younger age compared with women (71.4 versus 76.9 
years). Hypertension was the most prevalent comorbid 
condition (48.4%)—see Table 1 for details.
Overall Stroke Incidence
The overall IR of stroke from 1998 to 2017 was 109.21 
per 100 000 person-years (95% CI, 108.47–109.96). 
The IR was relatively steady between 1998 and 2003, 
with a peak incidence in 2004, and a subsequent decline 
in incidence till 2017, as shown in Figure 1A (details 
in Table II in the Data Supplement). The overall stroke 
incidence was higher in women (IR, 115.84 [95% CI, 
114.77–116.92]) compared with males (IR, 102.36 
[95% CI, 101.34–103.39]) with an IRR of 1.13 (95% 
CI, 1.12–1.15, P<0.0001). Stroke incidence increased in 
age groups older than the 55- to 59-year group—Fig-
ure 1B shows variations and Table III in the Data Supple-
ment provides the detailed results. Males aged 30 to 74 
years had higher stroke IRs compared with women, how-
ever, from age 75 the IRs were much higher in women.
Stroke Incidence by SES
After adjusting for the effects of age and sex (Table IV in 
the Data Supplement), we observed increasing incidence 
for every increase in IMD quintile. The rate of stroke inci-
dence among individuals in the lowest SES quintile was 
10% higher than the rate in the highest SES quintile 
(IRR, 1.10 [95% CI, 1.08–1.13]).
Subsequent Major Adverse Outcomes
Of the 82 774 individuals with incident stroke event, 
13 897 had a prior history of major adverse outcome and 
were excluded. Of the 68 877 individuals, mean age at 
incident stroke was 73.3 year (SD: 13.9), with 37 395 
(54.3%) being women. With respect to outcomes, 
47 500 (69.0%) had a MACE; 33 831 (49.1%) recur-
rent stroke (hemorrhagic stroke: 2378 [4.1%], ischemic 
stroke: 8842 [15.1%], stroke [not specified]: 22 611 
[38.6]); 9174 (13.3%) cardiovascular death; and 20 335 
(29.5%) all-cause death, occurring after the incident 
stroke events—Table V in the Data Supplement. There 
were 25 731 (68.8%) women with MACE outcome. Fig-
ure 2 shows the distribution of MACE, recurrent stroke, 
cardiovascular, and all-cause mortality outcomes pre-
sented by sex and across 5-year age bands. Most sub-
sequent outcomes occurred within 2 years of incident 
stroke—with the median follow-up time at which out-
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0.10 years (interquartile range, 0.02–1.49) for CVD-
related mortality and 1.74 years (interquartile range, 
0.51–4.42) for heart failure.
Incidence of Subsequent Major Adverse 
Outcomes
The overall MACE IR was 38.05 per 100 person-years 
(95% CI, 37.71–38.39). There was a steady rise in MACE 
incidence across the various age groups before peaking 
in the 80+ age group with a MACE IR of 45.31 per 100 
person-years as illustrated in Figure 3. With respect to 
the constituent MACE outcomes, women had a higher IR 
for CVD-related (4.13 versus 2.72 per 100 person-years 
respectively; IRR, 1.52 [1.45–1.58]) and all-cause mor-
tality (8.45 versus 6.21 per 100 person-years, respec-
tively; IRR, 1.36 [1.32–1.40]). The incidence of CHD and 
PVD were, however, higher in men. Table 2 details the 
sex variation in the incidence of the constituent MACE 
outcomes. In comparing women to men, the age- and 
SES-adjusted sex-specific IRR for MACE was 0.92 
(0.90–0.94), recurrent stroke: 0.96 (0.94–0.98), CVD-
related death: 1.00 (0.96–1.05), all-cause mortality: 0.96 
(0.93–0.98), CHD: 0.75 (0.69–0.81), PVD: 0.64 (0.54–
0.76), and heart failure: 0.93 (0.84–1.03).
Subsequent Major Adverse Outcomes by SES
After adjusting for age and sex, the rate ratio of MACE 
incidence among individuals in the lowest SES quintile 
was 9% more than the rate in the highest SES quintile 
(IRR, 1.09 [95% CI, 1.06–1.13]). There was no significant 
difference in recurrent stroke incidence between individ-
uals in the lowest and highest SES quintiles, IRR 1.00 
(95% CI, 0.97–1.04)—Table VI in the Data Supplement.
Sensitivity Analysis
For the sensitivity analysis, 20 571 (29.9%) of the 
68 877 patients with subsequent major adverse out-
come with 30 days of incident stroke were excluded. 
The remaining follow-up cohort (n=48 306) had similar 
Table 1. Demographic Characteristics of Individuals Aged 18 Years or Above With Incident Nonfatal 
Stroke, n=82 774
 Total, n=82 774
Men, n=38 160  
(46.1%)
Women, n=44 614 
(53.9%) P value
Age at incident stroke 74.3 (13.6) 71.4 (13.2) 76.9 (13.5) 0.0001
Type of incident stroke <0.001
 Hemorrhagic 7855 (9.5) 3842 (10.1) 4013 (9.0)  
 Ischemic 31 777 (38.4) 15 151 (39.7) 16 626 (37.3)  
 Not otherwise specified 43 142 (52.1) 19 167 (50.2) 23 975 (53.7)  
Socioeconomic status 0.170
 1 (Highest SES) 17 491 (21.1) 8209 (21.5) 9282 (20.8)  
 2 18 288 (22.1) 8359 (21.9) 9929 (22.3)  
 3 17 923 (21.7) 8259 (21.6) 9664 (21.7)  
 4 15 356 (18.6) 7001 (18.4) 8355 (18.7)  
 5 (Lowest SES) 13 569 (16.4) 6262 (16.4) 7307 (16.4)  
 Missing 147 (0.2) 70 (0.2) 77 (0.2)  
Ethnicity <0.001
 Asian 1063 (1.3) 579 (1.5) 484 (1.1)  
 Black 633 (0.8) 317 (0.8) 316 (0.7)  
 Mixed 116 (0.1) 64 (0.2) 52 (0.1)  
 Other 581 (0.7) 294 (0.8) 287 (0.6)  
 White 73 764 (89.1) 34 157 (89.5) 39 607 (88.8)  
 Unknown 6617 (8.0) 2749 (7.2) 3868 (8.7)  
Comorbid conditions
 Atrial fibrillation 10 316 (12.5) 4446 (11.7) 5870 (13.2) <0.001
 Diabetes 11 014 (13.3) 5630 (14.8) 5384 (12.1) <0.001
 Dyslipidemia 8892 (10.7) 3894 (10.2) 4998 (11.2) <0.001
 Hypertension 40 411 (48.8) 17 238 (45.2) 23 173 (51.9) <0.001
 TIA 17 365 (21.0) 7790 (20.4) 9575 (21.5) <0.001
Mean age at incident stroke reported with SD. % indicates percentage/proportion; n, total number; SES, socioeconomic status; 
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strata for SES as the excluded cohort. The proportion 
of patients with prestroke comorbid conditions varied 
between the excluded and remaining cohorts: atrial 
fibrillation (10.9% versus 8.7%, P<0.001), dyslipidemia 
(8.3% versus 10.0%, P<0.001), transient ischemia 
attack (8.2% versus 25.6%, P<0.001) respectively—
Table VII in the Data Supplement. There was a total of 
28 750 (59.5%) subsequent MACE outcomes recorded. 
Figure II and Table VIII in the Data Supplement show 
the distribution of subsequent MACE and its constitu-
ent outcomes: recurrent stroke (n=19 896, 41.2%), 
cardiovascular mortality (n=4797, 9.9%), and all-cause 
mortality (n=14 137, 29.3%). The overall IR for subse-
quent MACE was 23.14 per 100 person-years (95% CI, 
22.87–23.41), lower than the rate in the main analysis 
cohort (38.05 [95% CI  37.71–38.39]). Similar patterns 
for the incidence of subsequent major outcomes by 
sex and across the 5-year age groups, Figure III in the 
Data Supplement, were obtained. However, the IRs per 
100 person-years were slightly lower when compared 
with the main analysis—recurrent stroke (15.43 versus 
25.80), cardiovascular mortality (2.34 versus 3.44), and 
Figure 1. Trends in stroke incidence.
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all-cause mortality (6.58 versus 7.37), Table IX in the 
Data Supplement. The rate ratios by SES remained 
similar, Table X in the Data Supplement.
DISCUSSION
The incidence of stroke in the general population over 
the study period 1998 to 2019 was 109.20 per 100 000 
person-years, with a peak incidence in 2004 and then a 
steady decline over the following years. The incidence 
of stroke was higher in women. Our findings show the 
greater burden of major adverse outcomes observed 
in women when compared with men after first nonfatal 
stroke is largely accounted for by age and SES. The inci-
dence of first stroke and subsequent all-cause mortality 
are higher in individuals in the lowest compared with the 
highest SES groups.
Findings from a meta-analysis using the Global Bur-
den of Disease analytical technique (DisMod-MR), also 
estimated stroke incidence in the United Kingdom to be 
120 strokes per 100 000 population.23 A UK study with 
a smaller population of 1657 individuals with acute vas-
cular events in 9 Oxford primary care practices between 
2002 and 2005, reported an IR of 141 per 100 000 
population (95% CI, 127–156) for ischemic stroke with 
women having a higher IR than men (147 versus 136, 
respectively).9 By combining both primary care and hos-
pital data in our study, out-of-hospital stroke events are 
more likely to be captured,24 hence, more precise esti-
mates of incidence.
The Quality and Outcome Framework, a pay-for-per-
formance scheme covering a range of clinical and orga-
nizational areas in primary care, was introduced in the 
United Kingdom in April 2004.25 Stroke was one of the 
11 areas within the clinical domain. Although the Quality 
and Outcome Framework is a voluntary system, 99% of 
UK practices participate.25 During the first year, the level 
of achievement exceeded the governments anticipated 
level with an average of 83.4% of the allocated incentive 
payments claimed.26 The rise in stroke incidence in 2004 
could be attributed to better recording due to the intro-
duction of the Quality and Outcome Framework. This pay 
scheme also incentivized primary prevention, in particular, 
blood pressure and cholesterol control. These might have 
impacted on the incidence of stroke post 2004.
In England, Wales, and Northern Ireland, a study by 
Wang et al,27 reported the average age for incident stroke 
to be 72 years for men and 78 for women (71.4 and 76.8 
years, respectively, in our study). Consistent with other 
studies, women had a higher rate of major adverse out-
comes in the acute phase and were less likely to sur-
vive following stroke compared with males.28,29 Women 
have more severe strokes than men,28,29 and the quality 
of care received by women with stroke has been shown 
to be lower than that for men.30 These are considered to 
be other possible reasons for the observed sex differ-
ences in outcome. From a public health perspective, is 
there is a need to monitor and compare stroke burden 
over time.31 Population-based data sets such as elec-
tronic health records offer the opportunity to explore 
Figure 2. Distribution of subsequent major adverse outcomes presented by sex and 5-y age groups (n=68 877).
A, Major adverse cardiovascular event (n=47 500), (B) recurrent stroke (n=33 831), (C) cardiovascular-related mortality (n=9174), and (D) all-





















Akyea et al Incidence of Stroke and Major Adverse Outcomes
402  February 2021 Stroke. 2021;52:396–405. DOI: 10.1161/STROKEAHA.120.031659
stroke burden and its association with risk factors such 
as SES at a scale not previously possible.32 Quantifying 
that association between SES and stroke may help guide 
efforts aimed at reducing stroke burden, through local 
and focused secondary prevention interventions. Our 
study is consistent with a number of studies indicating 
person-level measures of lowest SES is associated with 
a higher risk of first-ever stroke.33,34 There is evidence 
of disparities in some aspects of stroke care and use of 
secondary prevention services for stroke—prescription of 
anticoagulation for atrial fibrillation, and timely admission 
to a specialist stroke unit.34
We were not able to identify any prior studies spe-
cifically describing the differences in IRs for subsequent 
major adverse outcomes after the first stroke. The clos-
est recent studies assessing major adverse outcomes 
after the first stroke have been in selected populations 
with ischemic stroke and above a predefined age.10,11 
Study by Sposato et al,11 investigating sex-specific risks 
(not incident rate) of incident MACE in patients ≥66 
years without known CVD comorbidities with first-ever 
ischemic stroke and propensity-matched individuals 
without stroke, found no sex difference in risk of incident 
MACE. Most women in their cohort were likely post-
menopausal hence higher testosterone/estradiol ratios 
or lower estrogen levels in women may have evened 
the risk of MACE across sexes.35 The higher rates of 
CHD and PVD in men compared with women in our 
study, are in keeping with previous studies.36,37 The risk 
of subsequent stroke within 90 days after acute tran-
sient ischemic attack or minor stroke has been shown 
to be high,38,39 and this could explain the high proportion 
transient ischemic attack recorded in individuals with a 
subsequent event within 30 days of incident stroke. In a 
study by Bray et al,34 patients from most deprived areas 
had lower 1-year survival compared with those from 
less deprived areas, however, the effect of SES was 
decreased after adjusting for baseline comorbidities. 
Efforts to reduce disparities in stroke and subsequent 
outcomes need to address not only the access to good 
quality health care but also the social determinants of 
health and vascular risk factors earlier in life.
To our knowledge, our study is the most recent larg-
est general population study to estimate the incidence 
of stroke and MACE following first stroke using multiple 
data linkages to maximize ascertainment of stroke and 
MACE outcomes. The failure to use linked primary care 
and hospital data have been shown to lead to a sub-
stantial (25%–50%) underestimation of the burden of 
cardiovascular disease like acute myocardial infarction.20 
CPRD, primary care database representative of the UK 
general population,12 is a rich source of longitudinal data 
and has been used to assess the incidence of a variety 
of health conditions.12,40 We, therefore, assume the inci-
dence of stroke and subsequent major adverse outcomes 
within the practices contributing data to CPRD accu-
rately reflects the incidence in the wider UK population.
Considering limitations of our study, case ascertain-
ment is a potential limitation as the study is reliant on 
the presence of clinical codes indicative of stroke or any 
of the subsequent major adverse outcomes. Inaccurate 
recording may affect the estimates as is the case with 
all epidemiological studies using routine medical records. 
However, considering these conditions are Quality and 
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Outcome Framework dependent and incentivized, the 
quality of the data remains high. It is not possible to be 
completely certain that subsequent coding of strokes 
does not relate to ongoing care of the initial stroke; 
hence, the rates for stroke maybe overestimated. Exclud-
ing patients without 12 months of data before incident 
stroke event minimizes the likelihood of overestimating 
stroke incidence in our study. Due to limited complete-
ness of ethnicity information in people who were reg-
istered with CPRD up until 2006,16 and small numbers 
within minority ethnic groups, ethnic differences were not 
assessed in our study.
CONCLUSIONS
This large population-based study linking national data-
bases has shown that stroke remains an important pub-
lic health problem. There is significant morbidity and 
mortality within 2 years of first stroke, with particular 
discrepancies across ages, sex, and SES. Public health 
policies and future clinical research need to investigate 
why this may occur, with a particular need to address 
disparities in outcomes for women and deprived popu-
lations. Evidence of variation in major adverse outcomes 
poststroke by demographic and socioeconomic char-
acteristics offers the opportunity to tailor secondary 
prevention and prioritize limited health care resources 
to those at greatest risk.
ARTICLE INFORMATION
Received July 4, 2020; final revision received November 28, 2020; accepted 
December 8, 2020.
Affiliations
Primary Care Stratified Medicine, Division of Primary Care, University of Not-
tingham, Nottingham, United Kingdom (R.K.A., Y.V., N.Q., J.K., S.F.W.). Institute of 
Cardiovascular Science, Faculty of Population Health Sciences (R.S.P., F.W.A.) and 
Health Data Research UK, Institute of Health Informatics (R.S.P., F.W.A.), Univer-
sity College London. Division of Population Health, Health Services Research and 
Primary Care (E.K.) and Division of Informatics, Imaging, and Data Sciences (E.K.), 
School of Health Sciences, Faculty of Biology, Medicine and Health, Manches-
ter Academic Health Science Centre (MAHSC), The University of Manchester, 
United Kingdom. Department of Internal Medicine, Faculty of Medicine, School 
of Health Sciences, University of Thessaly, Larissa, Greece (G.N.). Division Heart 
and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht 
University, the Netherlands (F.W.A.).
Acknowledgments
We thank the practices that contributed to the Clinical Practice Research Datalink 
(CPRD) GOLD. R.K. Akyea and Dr Weng were involved in the study concep-
tion. Analysis by R.K. Akyea with guidance from Drs Vinogradova and Weng. The 
article was drafted by R.K. Akyea. All authors reviewed and approved the final 
article. R.K. Akyea is the guarantor of the study.
Sources of Funding
R.K. Akyea is funded by the National Institute for Health Research School for 
Primary Care Research (NIHR-SPCR) PhD Studentship award, supervised by 
Drs Weng, Qureshi, and Kai. The views expressed are those of the authors and 
Table 2. Incidence of Subsequent Major Adverse Outcomes (n=68 877)
 Follow-up time (years) Cases Person-years*
Incidence rate (per 100 
person-years) Incidence rate ratio P value
MACE (all) 0.20 (0.03–1.51) 47 500 1200 38.05 (37.71–38.39)  0.0229
 Men 0.19 (0.03–1.49) 21 769 578.65 37.62 (37.12–38.12) Reference  
 Women 0.21 (0.03–1.51) 25 731 669.78 38.42 (37.95–38.89) 1.02 (1.00–1.04)  
Recurrent stroke (all) 0.16 (0.03–1.20) 33 831 1300 25.80 (25.53–26.08)  0.2582
 Men 0.14 (0.03–1.11) 15 975 623.23 25.63 (25.24–26.03) Reference  
 Women 0.19 (0.04–1.29) 17 856 688.09 25.95 (25.57–26.33) 1.01 (0.99–1.03)  
Cardiovascular mortality (all) 0.10 (0.02–1.49) 9174 2700 3.44 (3.38–3.52)  <0.0001
 Men 0.11 (0.02–1.79) 3516 1300 2.72 (2.63–2.81) Reference  
 Women 0.09 (0.02–1.27) 5658 1400 4.13 (4.02–4.24) 1.52 (1.45–1.58)  
All-cause mortality (all) 0.55 (0.05–3.20) 20 335 2800 7.37 (7.27–7.47)  <0.0001
 Men 0.66 (0.06–3.39) 8250 1300 6.21 (6.07–6.34) Reference  
 Women 0.49 (0.05–3.10) 12 085 1400 8.45 (8.30–8.60) 1.36 (1.32–1.40)  
Coronary heart disease (all) 1.71 (0.44–4.12) 2420 2600 0.95 (0.91–0.99)  <0.0001
 Men 1.72 (0.42–4.33) 1311 1200 1.06 (1.01–1.12) Reference  
 Women 1.71 (0.47–3.98) 1109 1300 0.84 (0.79–0.89) 0.79 (0.73–0.86)  
Peripheral arterial disease (all) 1.60 (0.55–3.94) 593 2600 0.23 (0.21–0.25)  0.0002
 Men 1.59 (0.52–3.91) 334 1300 0.26 (0.24–0.29) Reference  
 Women 1.60 (0.55–3.94) 259 1300 0.19 (0.17–0.22) 0.73 (0.62–0.87)  
Heart failure (all) 1.74 (0.51–4.42) 1482 2600 0.57 (0.54–0.60)  <0.0001
 Men 1.73 (0.52–4.29) 633 1300 0.50 (0.46–0.54) Reference  
 Women 1.74 (0.51–4.61) 849 1300 0.64 (0.60–0.68) 1.27 (1.15–1.41)  
All denotes both men and women; follow-up time: median follow-up time in years reported with interquartile range. MACE indicates major adverse cardiovas-
cular events.
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